Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) released its quarterly earnings data on Monday. The biotechnology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12, FiscalAI reports. Enanta Pharmaceuticals had a negative return on equity of 90.35% and a negative net margin of 106.80%.The company had revenue of $18.62 million for the quarter, compared to analysts’ expectations of $16.14 million.
Enanta Pharmaceuticals Stock Up 2.2%
Shares of NASDAQ:ENTA opened at $14.13 on Wednesday. The firm’s 50 day moving average price is $14.11 and its 200-day moving average price is $11.39. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $17.15. The stock has a market capitalization of $410.05 million, a PE ratio of -4.42 and a beta of 0.98.
Insider Activity at Enanta Pharmaceuticals
In other news, insider Yat Sun Or sold 2,390 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $34,009.70. Following the transaction, the insider owned 371,392 shares in the company, valued at $5,284,908.16. This trade represents a 0.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tara Lynn Kieffer sold 2,106 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $29,968.38. Following the sale, the insider directly owned 30,620 shares of the company’s stock, valued at approximately $435,722.60. The trade was a 6.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 11,961 shares of company stock worth $170,149. 11.48% of the stock is owned by company insiders.
Hedge Funds Weigh In On Enanta Pharmaceuticals
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.
View Our Latest Research Report on ENTA
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s directâacting antiviral regimens.
Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.
Featured Stories
- Five stocks we like better than Enanta Pharmaceuticals
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
